Trial reportJournal of clinical periodontology2019
Clinical benefits of systemic amoxicillin/metronidazole may depend on periodontitis severity and patients' age: An exploratory sub-analysis of the ABPARO trial.
Trial report in Journal of clinical periodontology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00707369 (Adjunctive Antimicrobial Therapy of Periodontitis), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adjunctive Antimicrobial Therapy of Periodontitis: Long-Term Effects on Disease Progression and Oral Microbiological Colonization
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Adjunctive systemic antimicrobials for the non-surgical treatment of periodontitis.The Cochrane database of systematic reviews · 2020Pooled it
- The role of the oral microbiota in the causal effect of adjunctive antibiotics on clinical outcomes in stage III-IV periodontitis patients.Microbiome · 2024Trial
- Clinical benefits of systemic amoxicillin/metronidazole may depend on periodontitis severity and patients' age: An exploratory sub-analysis of the ABPARO trial.Journal of clinical periodontology · 2019Trial
- [Short-term efficacy and influencing factors of systemic antibiotics as an adjunct to mechanical periodontal therapy for stages Ⅲ/Ⅳ periodontitis].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Exhaled Carbon Monoxide Indicates Persistent Subgingival Dysbiosis After Periodontal Therapy.Journal of clinical periodontology · 2026Article
- Periodontal Ecosystem and Clinical Implications of the Oral Microbiome: A Narrative Review.International journal of dentistry · 2026Review
- The butterfly effect: collateral damage and impacts of antimicrobial strategies on the oral microbiome.npj antimicrobials and resistance · 2025Review
- Long-Term Prognosis of Teeth With Class II Furcation Involvement: A Retrospective Cohort Study.Journal of clinical periodontology · 2025Article
- Association of supragingival plaque management with subgingival microbiota is moderated by adjunctive antibiotics in stage III-IV periodontitis patients during periodontal therapy.Journal of oral microbiology · 2025Article
- A retrospective study on the impact of different antibiotic regimens in non-surgical periodontal therapy on microbial loads and therapy outcomes.Frontiers in oral health · 2025Article
- Oral and periodontal manifestation related during human papilloma virus infections: Update on early prognostic factors.Heliyon · 2024Review
- Antibiotic Resistance among Fusobacterium, Capnocytophaga, and Leptotrichia Species of the Oral Cavity.Oral health & preventive dentistry · 2023Article
- Therapeutic effects of peptide P140 in a mouse periodontitis model.Cellular and molecular life sciences : CMLS · 2022Article
- The Role of Polymorphisms at the Interleukin-1, Interleukin-4, GATA-3 and Cyclooxygenase-2 Genes in Non-Surgical Periodontal Therapy.International journal of molecular sciences · 2022Article
- Akkermansia muciniphila and Its Pili-Like Protein Amuc_1100 Modulate Macrophage Polarization in Experimental Periodontitis.Infection and immunity · 2020Article
- Non-Surgical Periodontal Therapy with Adjunctive Amoxicillin/Metronidazole or Metronidazole When NoAntibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe aim was to identify benefit thresholds for clinical variables. We hypothesize, if variables fall below or exceed these threshold levels, systemic amoxicillin/metronidazole may contribute to reducing progression of periodontitis. MATERIAL &
methodsThis is an explorative per-protocol collective analysis (n = 345) conducted on the placebo-controlled, multi-centre ABPARO trial (ClinicalTrials.gov NCT00707369). Patients received debridement with systemic amoxicillin 500 mg/metronidazole 400 mg (3×/day, 7 days, n = 170) or placebo (n = 175) and maintenance therapy every three months. To identify thresholds, each of the following baseline characteristics was classified into two groups (≥threshold value/<threshold value): bleeding on probing, extent of pocket probing depth (PPD) ≥ 5 mm, mean clinical attachment level and age. Treatment effect (% of sites with new attachment loss ≥ 1.3 mm at 27.5 months post-treatment) was calculated.
resultsAdjunctive antimicrobials reduced median new attachment loss in patients < 55 years (5.2%), or with ≥ 35% PPD ≥ 5 mm (4.5%) or with a mean attachment level > 5 mm (5.2%) at baseline compared to the placebo (9.0%, 11.6%, and 12.5%, respectively; p < 0.005).
conclusionsThe clinical benefits of systemic amoxicillin/metronidazole may depend on periodontitis severity and patients' age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.